Lymphotoxin α stimulates proliferation and pro-inflammatory cytokine secretion of rheumatoid arthritis synovial fibroblasts

Cytokine. 2011 Feb;53(2):207-14. doi: 10.1016/j.cyto.2010.10.010. Epub 2010 Dec 15.

Abstract

Objective: TNFα plays a crucial role in rheumatoid arthritis (RA) by stimulating fibroblast-like synoviocytes (FLS). Lymphotoxin α (LTα) is a pro-inflammatory cytokine with significant homology to TNFα. We compared the effects of both cytokines on cultured RA FLS.

Methods: Receptor expression on RA FLS was analyzed by FACS. Cells were stimulated with LTα or TNFα and proliferation was measured by [3H]thymidine incorporation and secretion of inflammatory cytokines and metalloproteinase 3 by ELISA. Activation of MAP kinases and Akt was analyzed by Western blotting. Nuclear translocation of NFκB was visualized by immunofluorescence.

Results: 60-80% and 30-50% of the RA FLS tested expressed TNF receptors I and II, respectively, and 70-75% expressed HVEM. LTα induced RA FLS proliferation at the same level of TNFα, which was blocked by etanercept. Both LTα and TNFα induced activation of MAP kinases ERK1/2 and p38 as well as Akt. 95-98% of FLS showed nuclear translocation of NFκB after stimulation with either cytokines. LTα and TNFα were potent to induce secretion of IL-6, IL-8 and metalloproteinase 3 in FLS.

Conclusion: LTα is as effective as TNFα in stimulating RA FLS. Blocking both cytokines might allow a better control of inflammation and synovial proliferation in RA.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Arthritis, Rheumatoid / pathology*
  • Cell Nucleus / drug effects
  • Cell Nucleus / metabolism
  • Cell Proliferation / drug effects
  • Cytokines / metabolism*
  • Enzyme Activation / drug effects
  • Etanercept
  • Extracellular Signal-Regulated MAP Kinases / metabolism
  • Fibroblasts / drug effects
  • Fibroblasts / enzymology
  • Fibroblasts / metabolism*
  • Fibroblasts / pathology
  • Humans
  • Immunoglobulin G / pharmacology
  • Inflammation Mediators / metabolism*
  • Lymphotoxin-alpha / pharmacology*
  • Matrix Metalloproteinase 3 / metabolism
  • NF-kappa B / metabolism
  • Protein Kinase Inhibitors / pharmacology
  • Protein Transport / drug effects
  • Proto-Oncogene Proteins c-akt / metabolism
  • Receptors, Tumor Necrosis Factor
  • Receptors, Tumor Necrosis Factor, Member 14 / metabolism
  • Receptors, Tumor Necrosis Factor, Type I / metabolism
  • Receptors, Tumor Necrosis Factor, Type II / metabolism
  • Synovial Fluid / cytology*
  • Synovial Fluid / drug effects
  • p38 Mitogen-Activated Protein Kinases / metabolism

Substances

  • Cytokines
  • Immunoglobulin G
  • Inflammation Mediators
  • Lymphotoxin-alpha
  • NF-kappa B
  • Protein Kinase Inhibitors
  • Receptors, Tumor Necrosis Factor
  • Receptors, Tumor Necrosis Factor, Member 14
  • Receptors, Tumor Necrosis Factor, Type I
  • Receptors, Tumor Necrosis Factor, Type II
  • TNFRSF14 protein, human
  • Proto-Oncogene Proteins c-akt
  • Extracellular Signal-Regulated MAP Kinases
  • p38 Mitogen-Activated Protein Kinases
  • MMP3 protein, human
  • Matrix Metalloproteinase 3
  • Etanercept